Objective To investigate the value of gastrin 17 (G-17) combined with pepsinogen (PG) serological detection in early diagnosis and diagnosis of gastric cancer. Methods A total of 120 patients with gastric diseases admitted to our hospital from January 2016 to January 2017 were enrolled. The patients were examined for gastrin and pepsinogen levels, and painless gastroscopy was used to examine the patient's disease confirmation, and the results of gastroscopy were standard, and the value of gastrin 17 combined with pepsinogen detection in the early diagnosis of gastric cancer was studied. Results In 120 patients, 60 cases of gastric ulcer, 30 cases of superficial gastritis, 20 cases of atrophic gastritis and 10 cases of gastric cancer were examined by gastroscopy. Among them, gastrin 17 showed positive patients in 5 cases, the positive rate was 4.1％; pepsinogen test showed positive patients in 4 cases, the positive rate was 3.3％; the combined test positive rate was 8/6.6％, the three differences were statistical significant (P＜0.05). In addition, the results of gastrin-17 and pepsinogen in patients with gastric ulcer, superficial gastritis, atrophic gastritis and gastric cancer patients (18.9 ±4.5) ρmol/L, (59.2 ±21.3) μg/L, (15.9 ±6.2) μg/L, with significant difference (P ＜0.05).Conclusion Gastrin-17 combined with pepsinogen serological detection has a significant value in the early screening and diagnosis of gastric cancer.%目的 对胃泌素17(G-17)联合胃蛋白酶原(PG)血清学检测在胃癌早期筛查诊断中的价值作用进行研究.方法 选取该院2016年1月-2017年1月收治的120例胃部疾病患者,临床对患者胃泌素-17、胃蛋白酶原水平进行检测,同时采用无痛胃镜检查对患者疾病情况进行检查确认,并胃镜检查结果为标准,对胃泌素17联合胃蛋白酶原检测在胃癌早期诊断的价值进行研究.结果 120例患者,经胃镜检查显示,胃溃疡60例、浅表性胃炎30例、萎缩性胃炎20例、胃癌患者10例.其中,胃泌素-17检查显示阳性患者5例,阳性率为4.1％;胃蛋白酶原检测显示阳性患者4例,阳性率为3.3％;联合检查阳性率为8/6.6％,三者对比差异有统计学意义(P＜0.05).此外,对胃溃疡、浅表性胃炎、萎缩性胃炎患者胃泌素17与胃蛋白酶原检测结果与胃癌患者(18.9±4.5)ρmol/L、(59.2±21.3)μg/L、(15.9±6.2)μg/L对比差异有统计学意义(P＜0.05).结论 胃泌素-17联合胃蛋白酶原血清学检测在胃癌早期筛查诊断中具有较为显著的价值作用.
展开▼
